Skip to main navigation
Acadia
  • Home
  • Contact
  • Home
  • About
    • Management Team
    • Board Of Directors
    • Our Purpose, Mission & Values
    • History
  • Product
  • Pipeline
    • Dementia-Related Psychosis
    • Rett syndrome
    • Schizophrenia – Negative Symptoms
    • Early Stage Clinical Programs
  • Resources
    • Parkinson’s Disease Psychosis
    • Clinical Trials
    • Investigator Initiated Trials
    • Medical Education Grants
    • Scientific Publications
  • Partnering
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • Sec Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
  • Media
  • Careers
  • Contact
  • About
    • Management Team
    • Board Of Directors
    • Our Purpose, Mission & Values
    • History
  • Product
  • Pipeline
    • Dementia-Related Psychosis
    • Rett Syndrome
    • Schizophrenia – Negative Symptoms
    • Early Stage Clinical Programs
  • Resources
    • Parkinson’s Disease Psychosis
    • Clinical Trials
    • Investigator Initiated Trials
    • Medical Education Grants
    • Scientific Publications
  • Partnering
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
  • Media
  • Careers
banner

News Releases

Keyword Search

None | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
Date Title
04/21/21
Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
04/05/21
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
03/08/21
Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
02/24/21
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
02/19/21
Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
02/18/21
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
02/10/21
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
01/27/21
Acadia Pharmaceuticals Announces Commercial Leadership Change

Investor Relations

  • INVESTORS
  • STOCK INFORMATION
  • NEWS RELEASES
  • EVENTS & PRESENTATIONS
  • SEC FILINGS
  • CORPORATE GOVERNANCE
  • FINANCIAL INFORMATION
  • ANALYST COVERAGE
  • ANNUAL REPORT AND PROXY
  • INFORMATION REQUEST
  • EMAIL ALERTS
  • Investor Contact

Shareholder Tools

  • Print Page
  • RSS Feeds
  • Share
  • Privacy
  • Cookies
  • Privacy
    Shield
  • Terms
  • Email

© 2021 Acadia Pharmaceuticals Inc. Acadia and NUPLAZID are registered
trademarks of Acadia Pharmaceuticals Inc. All rights reserved.

This website uses cookies to improve and customize your experience on our website. By using this website without changing your cookie settings in your browser, you agree to our use of cookies. For further details on cookies, how we use cookies and how to delete or block the use of cookies, please read our Cookie Policy.

ACCEPT